
The regulatory framework governing therapeutic vapes
Prescriber Information Hub The regulatory framework governing therapeutic vapes Since 2021, vapes may...
Prescriber Information Hub The regulatory framework governing therapeutic vapes Since 2021, vapes may...
Pharmacist Information Hub The scientific consensus on vaping The gold standard for understanding...
Prescriber Information Hub Understanding the current vaping laws GPs have prescribed vaping products...
Prescriber hub S3 vapes: Why GP visits are likely to increase from...
Prescriber hub Standards framework for the new Nicovape® Q System Prescriber hub...
Prescriber hub Questions you need to ask before prescribing an NVP brand...
Prescriber hub PNVP References Therapeutic Goods (Medicines and OTG—Authorised Supply) Rules 2022....
Prescriber hub Frequently Asked Questions Is Nicovape® Q Safe? There isn’t enough...
Prescriber hub Helping your patient start using Nicovape® Q Setting up your...
This website is a source of educational content for Australian-registered healthcare professionals only. You must not use the content for any other purpose. If you are a patient seeking medical advice please see your healthcare professional.
By accessing this website you are agreeing that you are an Australian-registered healthcare professional with a current AHPRA registration and are entitled to access this content. Your use of this content is also subject to our Terms of Use and Privacy Policy.
With low-concentration vapes becoming S3 from 1 October 2024, there is much confusion as to what is expected of pharmacists, and how the market is likely to play out.
Liber Pharmaceuticals has worked closely with thousands of pharmacists and prescribers for the last three years to ensure that you are able to supply therapeutic vapes effectively.
Join us as we share our thoughts on the following:
Each session will have at least 30 minutes for Q&A.